Epidermal growth factor receptor (EGFR), the receptor for members of the epidermal growth
factor family, regulates cell proliferation and signal transduction; moreover, EGFR is related …

Lung cancer accounts for a relatively high proportion of malignant tumors. As the most
prevalent type of lung cancer, non-small cell lung cancer (NSCLC) is characterized by high …

PURPOSE Trastuzumab deruxtecan (T-DXd) 5.4 and 6.4 mg/kg showed robust antitumor
activity in multiple cancer indications; however, T-DXd 5.4 mg/kg has not been evaluated in …

Non-small-cell lung cancer (NSCLC) represents a heterogeneous group of malignancies
consisting essentially of adenocarcinoma (ADC) and squamous cell carcinoma (SCC) …

Lung cancer is the leading cause of cancer death worldwide. In the past decade EGFR, ALK
and ROS1 TKIs lead to an unprecedented survival improvement of oncogene-addicted …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have been first-line
therapy in the treatment of non-small cell lung cancer (NSCLC) harboring EGFR sensitive …

High expression or aberrant activation of epidermal growth factor receptor (EGFR) is related
to tumor progression and therapy resistance across cancer types, including non-small cell …

In non-small cell lung cancer (NSCLC) with human epidermal growth factor receptor 2
(HER2) alterations, chemotherapy remains the standard treatment over a decade, due to the …

Before the introduction of tyrosine kinase inhibitors (TKIs) for a particular subgroup of
patients, despite platinum-based combination chemotherapy, the majority of patients …

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) represents a paradigm
shift in the treatment of non-small cell lung cancer (NSCLC) patients and has been the first …